ACADIA Pharmaceuticals Inc. Financials

Market Capitalization $3.51 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	15.29
Forward PE	25.55
Price to Sales TTM	$3.52
Price to Book MRQ	$4.58
Enterprise to Revenue	3.00
Enterprise to EBITDA	29.36

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	22.97%
Operating Margin	7.90%
Return on Assets TTM	5.56%
Return on Equity TTM	37.24%

Income Statement

Revenue TTM	$996,283,008
Revenue per Share TTM	$5.99
Quarterly Revenue Growth	18.70%
Gross Profit TTM	$595,166,016
EBITDA	$101,665,000
Net Income to Common TTM	$228,883,008
Diluted EPS TTM	$1.37
Quarterly Earnings Growth YoY	14.70%

Balance Sheet

Total Cash MRQ	$681,577,024
Total Cash per Share MRQ	$4.07
Total Debt MRQ	$
Total Debt to Equity MRQ	7.32
Current Ratio MRQ	2.88
Book Value per Share MRQ	$4.58

Cash Flow

Operating Cash Flow TTM	$148,963,008
Levered Free Cash Flow TTM	$19,273,376

ACAD Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	166,708,856
Float Shares	114,821,945
Avg 10 Volume	2,300,200
Avg 30 Volume	None
Shares Short	15,435,884
Short Ratio	6.15
Short % of Shares	14.53%
% Held by Insiders	0.57%
% Held by Institutions	105.53%

Stock Price Summary

Beta	0.65
Fifty Two Week Low	$13.40
Fifty Two Week High	$25.23
Fifty Two Week Change	23.01%
Day 50 MA	$19.83
Day 200 MA	$17.57

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date